Evotec SE EVT.DE
Healthcare
XETRA
Loading live quote…
$4.66
+0.06
(+1.39%)
Price Chart
About Evotec SE I
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General…
Recent Quarters
| Quarter | Revenue | Net Income | EPS (dil.) | Gross Margin |
|---|---|---|---|---|
| 2026 Q1 | — | $-121,936,000 | -0.69 | -1.0% |
| 2025 Q4 | — | $14.6M | — | 31.0% |
| 2025 Q3 | — | $-43,087,000 | — | 0.0% |
| 2025 Q2 | — | $-43,478,000 | -0.24 | 5.0% |
EVT.DE — Latest Coverage
